

Summary of risk management plan for
AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per
actuation, nasal spray suspension
(Azelastine hydrochloride / Fluticasone propionate)

This is a summary of the risk management plan (RMP) for AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension. The RMP details important risks of AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension, how these risks can be minimised, and how more information will be obtained about AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension's risks and uncertainties (missing information).

AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension should be used.

Important new concerns or changes to the current ones will be included in updates of AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension's RMP.

I. The medicine and what it is used for

AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension is authorised for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient in adults and adolescents (12 years and older) (see SmPC for the full indication). It contains Azelastine hydrochloride / Fluticasone propionate as the active substance and it is given by intranasal administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension, together with measures to minimise such risks and the proposed studies for learning more about AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;

Important advice on the medicine's packaging;

The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;

The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension.

Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II. B Summary of important risks

Not applicable.

II. C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms / 50 micrograms per actuation, nasal spray suspension.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for AZELASTINE/FLUTICASONE SUBSTIPHARM 137 micrograms 50 micrograms per actuation, nasal spray suspension.